Genomic Profiling Systems Appoints Director of Technical Services; Dr. David L. Jones to Lay Groundwork for Validation of Growth Direct(TM) System in Pharmaceutical Manufacturing.BEDFORD, Mass. -- Genomic Profiling Systems (GPS) announced that David L. Jones, Ph.D. has joined their company in the capacity of Director of Technical Services. He comes to GPS from Wyeth Biopharma in Dublin where he has been Manager of Microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. Test Technologies since 2003. Dr. Jones will be applying his world-renowned expertise in applied microbiology to the commercialization of the Company's initial product offering, the Growth Direct(TM) System, for rapid pharmaceutical microbiology Pharmaceutical microbiology is the part of industrial microbiology that is responsible for creating medications. All parenteral drugs, including many oral drugs, must go through rigorous microbiological testing in order to validate certain compounds by USP regulations. quality control (QC). Dr. Jones will head up a team of microbiologists to support the evaluation and validation of this revolutionary system that will allow pharmaceutical companies to save costs and improve manufacturing efficiencies by significantly reducing the time required to test for microbial contaminants. The Growth Direct(TM) System is scheduled for release in early 2006. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Bob Linke, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , "We could not be more pleased to have an individual of Dr. Jones' caliber and reputation in our organization at a pivotal moment in our history. As our company is poised to transform rapid microbiology quality control to save pharmaceutical manufacturers time and money, the requirement for an individual with experience on both the end-user and manufacturer side is essential. This is what we have found in Dr. Jones, who brings years of stellar achievement to his role at GPS. Dr. Jones' name has become synonymous with synonymous with adjective equivalent to, the same as, identical to, similar to, identified with, equal to, tantamount to, interchangeable with, one and the same as the field of rapid microbial analysis. As a contributing author to seminal publications such as Laboratory Validation, A Practioner's Guide and the European Journal European Journal is a weekly Deutsche Welle (DW) news program produced in English. It is broadcast from Brussels, Belgium and primarily covers political and economic developments across the European Union and the rest of Europe, as well as issues of particular concern to of Parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. Sciences for which he was awarded the medal for best scientific article of the year in 1999, his reputation in the niche of rapid microbiology has been solidified. We look to Dr. Jones as the critical link to implementation of Growth Direct(TM) technology in major pharmaceutical companies throughout the world." Dr. Jones ushered other rapid industrial microbiology tests to the market while at Chemunex SA in Paris from 1997 to 2002 and developed novel clinical assay technology while with Anagen anagen /an·a·gen/ (an´ah-jen) the first phase of the hair cycle, during which synthesis of hair takes place. an·a·gen n. The growth phase of the hair cycle during which new hair is formed. Ltd in the UK from 1990-1996. At Unipath Ltd, he worked on the development of the Clearblue line in the 1980s that became the standard in point of care pregnancy testing in today's products. Dr. Jones holds a graduate degree from Brunel University in applied biochemistry and obtained his doctorate from St. Mary's Hospital Medical School in London in the field of steroid endocrinology. "I look forward to the opportunity to apply the principles of validation that I have elaborated for the pharmaceutical industry to the introduction of the Growth Direct(TM) System. Technology that can enable earlier detection of contaminants will have far reaching quality and economic benefits for the producers of pharmaceutical and biopharmaceutical products worldwide." Dr. Jones commented. About Genomic Profiling Systems Genomic Profiling Systems, based in Bedford, MA, is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. developing groundbreaking products that address significant unmet needs in pharmaceutical manufacturing, the food industry, healthcare, and biodefense global markets. The Company's automated testing platforms and products deliver rapid, ultra-sensitive detection of microbiological contamination, infection, and disease markers. In early 2006, GPS will launch its first product, the Growth Direct(TM) System, which rapidly detects microbiological contamination in pharmaceutical products. This new tool will help pharmaceutical manufacturers improve their manufacturing efficiencies in accordance with the FDA's Process Analytical Technology Process Analytical Technology (PAT) has been defined by the United States Food and Drug Administration (FDA) as a mechanism to design, analyze, and control pharmaceutical manufacturing processes through the measurement of critical process parameters and quality attributes. (PAT) initiative. For more information, go to www.genprosys.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion